Objective  To explore the efficacy and safety of sacubitril-valsartan in treating hypertension.

Methods  CNKI, WanFang Data, CBM, PubMed, The Cochrane Library, Embase, Web of Science were searched electronically to collect randomized controlled trials of sacubitril-valsartan for the treatment of hypertension from inception of the databases to August 1, 2023. Two reviewers independently browsed the literatures, extracted data, and evaluated the risk of bias. RevMan 5.3 software was used for a Meta-analysis.

Results  A total of 10 randomized controlled trials involving 4 103 patients were included. The results of the Meta-analysis showed that there was a statistically significant difference in the antihypertensive effect of sacubitril-valsartan before and after treatment compared with the control intervention [SBP: MD=6.26, 95%CI(4.10, 8.42), P<0.001; DBP: MD=4.06, 95%CI(1.78, 6.34), P<0.001]; the difference in blood pressure attainment was statistically significant [RR=1.22, 95%CI(1.08, 1.38), P=0.002]; the incidence of adverse reactions after the application of sacubitril-valsartan was not significantly different from that of the control group [RR=1.04, 95%CI(0.94, 1.14), P>0.05].

Conclusion  Sacubitril-valsartan has a definite efficacy and high safety in the treatment of hypertension.

1.国家心血管病中心. 中国心血管健康与疾病报告2020[M]. 北京: 科学出版社, 2021. [National Center for Cardiovascular Diseases. Chinese cardiovascular health and disease report 2020[M]. Beijing: Science Press, 2021.]

2.Chow CK, Teo KK, Rangarajan S, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries[J]. JAMA, 2013, 310(9): 959-968. DOI: 10.1001/jama.2013.184182.

3.Abdin A, Schulz M, Riemer U, et al. Sacubitril/valsartan in heart failure: efficacy and safety in and outside clinical trials[J]. ESC Heart Fail, 2022, 9(6): 3737-3750. DOI: 10.1002/ehf2.14097.

4.Jackson AM, Jhund PS, Anand IS, et al. Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction[J]. Eur Heart J, 2021, 42(36): 3741-3752. DOI: 10.1093/eurheartj/ehab499.

5.Rakugi H, Kario K, Yamaguchi M, et al. Efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study[J]. Hypertens Res, 2022, 45(5): 824-833. DOI: 10.1038/s41440-021-00819-7.

6.Schmieder RE, Wagner F, Mayr M, et al. The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study[J]. Eur Heart J, 2017, 38(44): 3308-3317. DOI: 10.1093/eurheartj/ehx525.

7.Wang TD, Tan RS, Lee HY, et al. Effects of sacubitril/valsartan (LCZ696) on natriuresis, diuresis, blood pressures, and NT-proBNP in salt-sensitive hypertension[J]. Hypertension, 2017, 69(1): 32-41. DOI: 10.1161/HYPERTENSIONAHA.116.08484.

8.中国高血压防治指南修订委员会, 高血压联盟(中国), 中华医学会心血管病学分会, 等. 中国高血压防治指南(2018年修订版)[J]. 中国心血管杂志, 2019, 24(1): 24-56. [Chinese Guidelines for the Management of Hypertension, Chinese Hypertension League, Chinese Society of Cardiology of Chinese Medical Association, et al. 2018 Chinese guidelines for the management of hypertension[J]. Chinese Journal of Cardiovascular Medicine, 2019, 24(1): 24-56.] DOI: 10.3969/j.issn.1007-5410.2019.01.002.

9.Mancia G, Kreutz R, Brunström M, et al. 2023 ESH guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA)[J]. J Hypertens, 2023. DOI: 10.1097/HJH.0000000000003480.

10.Higgins JPT, Chandler J, Cumpston M, et al. Cochrane handbook for systematic reviews of interventions version 6.3 (updated February 2022)[M]. Cochrane, 2022.

11.杨娟, 郑青山. Meta分析的统计学方法[J]. 中国临床药理学与治疗学, 2005, 10(11): 1309-1314. [Yang J, Zheng QS. Statistical methods of Meta-analysis[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(11): 1309-1314.] DOI: 10.3969/j.issn.1009-2501.2005.11.023.

12.康德英, 洪旗, 刘关键, 等. Meta分析中发表性偏倚的识别与处理[J]. 中国循证医学杂志, 2003, 3(1): 45-49. [Kang DY, Hong Q, Liu GJ, et al. Investigating and dealing with publication bias in Meta analysis[J]. Chinese Journal of Evidence-Based Medicine, 2003, 3(1): 45-49.] DOI: 10.3969/j.issn.1672-2531.2003.01.010.

13.Kario K, Sun N, Chiang FT, et al. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study[J]. Hypertension, 2014, 63(4): 698-705. DOI: 10.1161/HYPERTENSIONAHA.113.02002.

14.Supasyndh O, Wang J, Hafeez K, et al. Efficacy and safety of sacubitril/valsartan (LCZ696) compared with olmesartan in elderly Asian patients (≥65 years) with systolic hypertension[J]. Am J Hypertens, 2017, 30(12): 1163-1169. DOI: 10.1093/ajh/hpx111.

15.Williams B, Cockcroft JR, Kario K, et al. Effects of sacubitril/valsartan versus olmesartan on central hemodynamics in the elderly with systolic hypertension: the PARAMETER study[J]. Hypertension, 2017, 69(3): 411-420. DOI: 10.1161/HYPERTENSIONAHA.116.08556.

16.Cheung DG, Aizenberg D, Gorbunov V, et al. Efficacy and safety of sacubitril/valsartan in patients with essential hypertension uncontrolled by olmesartan: a randomized, double-blind, 8-week study[J]. J Clin Hypertens (Greenwich), 2018, 20(1): 150-158. DOI: 10.1111/jch.13153.

17.Huo Y, Li W, Webb R, et al. Efficacy and safety of sacubitril/valsartan compared with olmesartan in Asian patients with essential hypertension: a randomized, double-blind, 8-week study[J]. J Clin Hypertens (Greenwich), 2019, 21(1): 67-76. DOI: 10.1111/jch.13437.

18.赖朝辉, 刘迎午, 王禹, 等. 沙库巴曲缬沙坦钠对射血分数减低的心力衰竭合并高血压患者血压及相关指标变化的研究[J]. 中华老年心血管病杂志, 2022, 24(1): 11-13. [Lai CH, Liu YW, Wang Y, et al. Change of BP and related indexes in HFrEF patients with hypertension after sacubitril valsartan treatment[J]. Chinese Journal of Geriatric Heart Brain and Vessel Diseases, 2022, 24(1): 11-13.] DOI: 10.3969/j.issn.1009-0126.2022.01.004.

19.Lyu TJ, Liu Y, Zhang H, et al. Clinical observation of sacubitril valsartan sodium in the treatment of resistant hypertension: a randomized clinical trial[J]. Front Cardiovasc Med, 2022, 9: 1099043. DOI: 10.3389/fcvm.2022.1099043.

20.Kario K, Rakugi H, Yarimizu D, et al. Twenty-four-hour blood pressure-lowering efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension based on nocturnal blood pressure dipping status: a post hoc analysis of data from a randomized, double-blind multicenter study[J]. J Am Heart Assoc, 2023, 12(8): e027612. DOI: 10.1161/JAHA.122.027612.

21.Lang CC, Struthers AD. Targeting the renin-angiotensin-aldosterone system in heart failure[J]. Nat Rev Cardiol, 2013, 10(3): 125-134. DOI: 10.1038/nrcardio.2012.196.

22.中国老年医学学会高血压分会, 北京高血压防治协会, 国家老年疾病临床医学研究中心(中国人民解放军总医院,首都医科大学宣武医院). 中国老年高血压管理指南2023[J]. 中华高血压杂志, 2023, 31(6): 508-538. [Hipertension Branch of Chinese Geriatrics Society, Beijing Hypertension Association, National Clinical Research Center for Geriatric Diseases (Chinese PLA General Hospital, Xunwu Hospital Capital Medical University). Guidelines for the management of hypertension in the elderly in China 2023[J]. Chinese Journal of Hypertension, 2023, 31(6): 508-538.] DOI: 10.16439/ji.ssn.1673-7245.2023.06.003.

23.Ito S, Satoh M, Tamaki Y, et al. Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction[J]. Hypertens Res, 2015, 38(4): 269-275. DOI: 10.1038/hr.2015.1.

24.张跃, 李宁, 邱健, 等. 血管紧张素受体脑啡肽酶抑制剂沙库巴曲缬沙坦治疗高血压的研究进展[J]. 中华高血压杂志, 2021, 29(6): 519-524. [Zhang Y, Li N, Qiu J, et al. Research progress of angiotensin receptor neprilypridate inhibitor sacubitril valsartan in the treatment of hypertension[J]. Chinese Journal of Hypertension, 2021, 29(6): 519-524.] DOI: 10.16439/j.issn.1673-7245.2021.06.004.

25.王珍, 张永红. NNT在疗效评价研究中的应用[J]. 中国卫生统计, 2010, 27(5): 549-551. [Wang Z, Zhang YH. Application of NNT in efficacy evaluation[J]. Chinese Journal of Health Statistics, 2010, 27(5): 549-551.] DOI: 10.3969/j.issn.1002-3674.2010.05.034.

26.郑丽, 张续乾, 孙雪林, 等. 沙库巴曲缬沙坦钠治疗高血压有效性和安全性的Meta分析[J]. 中国药物警戒, 2022, 19(10): 1118-1122, 1135. [Zheng L, Zhang XQ, Sun XL, et al. Effect and safety of sacubatril/valsartan sodium in the treatment of hypertension: a Meta-analysis[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1118-1122, 1135.] DOI: 10.19803/j.1672-8629.20210154.

27.郭娇, 刘璐瑶, 刘新灿. 沙库巴曲缬沙坦治疗高血压有效性和安全性的Meta分析[J]. 中国循证医学杂志, 2023, 23(6): 679-683. [Guo J, Liu LY, Liu XC. Efficacy and safety of sacubitril-valsartan in the treatment of hypertension: a Meta-analysis[J]. Chinese Journal of Evidence-Based Medicine, 2023, 23(6): 679-683.] DOI: 10.7507/1672-2531.202301084.